×
About 465 results

ALLMedicine™ Acute Bronchospasm Center

Research & Reviews  41 results

Ammonia Toxicity Treatment & Management
http://emedicine.medscape.com/article/820298-treatment

Apr 11th, 2022 - Approach Considerations Management of toxic exposure to ammonia is largely supportive. Decontaminate the patient (if that was not done at the site of exposure) and support airway, breathing, and circulation (ABCs) as necessary. Provide warmed humi...

Unusual Presentation of Atrial Myxoma: A Case Report and Review of the Literature.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105743
The American Journal of Case Reports; Jaravaza DR, Lalla U et. al.

May 4th, 2021 - BACKGROUND Although rare, atrial myxoma is the most common benign cardiac tumor. The recognized triad of presenting symptoms relates to constitutional, embolic, and obstructive effects produced by the tumor. However, the presentation may be non-sp...

Computed Tomography Scan Evidence of Bronchospasm and Its Resolution During Computed To...
https://doi.org/10.1213/XAA.0000000000001388
A&A Practice; Munaf M, Gadhinglajkar S et. al.

Mar 9th, 2021 - Bronchospasm in children is common; however, due to its sudden nature, radiographic correlation is uncommon. We planned a computed tomography (CT) coronary angiogram for a 5-year-old child for evaluation of Kawasaki disease. The child started to d...

Theophylline Level
https://emedicine.medscape.com/article/2090395-overview

Feb 10th, 2020 - Reference Range Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet. [1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke...

Theophylline Level
https://emedicine.medscape.com/article/2090395-print

Feb 10th, 2020 - Theophylline is a methylxanthine, a class of molecule similar to the xanthines caffeine and theobromine found in a normal diet.[1, 2] It has a half-life of 8 hours in a healthy person but decreases to 4-5 hours in people who smoke.[3] In the blood...

see more →

Drugs  108 results see all →

Clinicaltrials.gov  5 results

Chronic Beta-blockade and Cardiopulmonary Exercise in COPD
https://clinicaltrials.gov/ct2/show/NCT02380053

Jun 24th, 2019 - Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death. In fact, by 2020, the World Health Organization predicts that COPD will become the third leading cause of death (currently fourth), and the fifth leading cause of ...

Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial
https://clinicaltrials.gov/ct2/show/NCT03000413

Dec 22nd, 2016 - Despite few scientific evidence that could support the use of ketamine in adult patients undergoing acute bronchospasm requiring mechanical ventilation (MV), ketamine is largely employed in this setting. The aim of this study is therefore assess m...

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
https://clinicaltrials.gov/ct2/show/NCT02150499

Apr 8th, 2016 - This is a study to determine the safety and tolerability of cumulative dosing with levalbuterol tartrate HFA inhalation aerosol MDI using a valved holding chamber and facemask in pediatric subjects birth to ≤ 48 months of age with acute bronchospa...

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
https://clinicaltrials.gov/ct2/show/NCT00819637

Apr 6th, 2015 - Acute bronchospasm associated with exacerbations of asthma is a common problem. Currently the mainstay of treatment is inhalation albuterol, either levalbuterol or racemic mixture, in repetitive fashion depending on the resolution of the airways o...

Effects of Cardioselective β-blockers on Dynamic Hyperinflation in COPD
https://clinicaltrials.gov/ct2/show/NCT01273298

Jun 23rd, 2011 - Beta-blockers are indicated in the management of numerous medical conditions including angina pectoris, myocardial infarction, hypertension, congestive heart failure, cardiac arrhythmia, systemic hypertension, as well as to reduce complications in...

see more →

News  32 results

FDA OKs First-in-Class Biologic for Severe Asthma
https://www.medpagetoday.com/allergyimmunology/asthma/96288

Dec 20th, 2021 - The FDA approved the only biologic for severe asthma without any phenotype or biomarker limitations, manufacturers AstraZeneca and Amgen announced Friday. The first-in-class biologic tezepelumab-ekko (Tezspire) is indicated as an add-on maintenanc...

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/pulmonary-health-hub/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic?channel=94
Christopher Palmer

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA approves benralizumab autoinjector for eosinophilic asthma
https://www.mdedge.com/chestphysician/article/209478/asthma/fda-approves-benralizumab-autoinjector-eosinophilic-asthma
Christopher Palmer, MDedge News

Oct 4th, 2019 - The Food and Drug Administration has approved a prefilled, single-use autoinjector of benralizumab (Fasenra) for self-administration in adults with eosinophilic asthma, according to a press release from AstraZeneca. Benralizumab is already approve.

FDA approves mepolizumab for severe eosinophilic asthma in younger kids
https://www.mdedge.com/pediatrics/article/208133/asthma/fda-approves-mepolizumab-severe-eosinophilic-asthma-younger-kids
Christopher Palmer

Sep 13th, 2019 - The Food and Drug Administration has approved mepolizumab (Nucala, 40 mg subcutaneous) for patients aged 6-11 years with severe eosinophilic asthma, according to a release from GlaxoSmithKline, which developed the drug. This is the first targeted.

FDA approves Nucala’s new at-home formulations
https://www.mdedge.com/chestphysician/article/202475/asthma/fda-approves-nucalas-new-home-formulations
Christopher Palmer, MDedge News

Jun 6th, 2019 - The Food and Drug Administration has approved two new formulations for the anti–interleukin-5 biologic mepolizumab (Nucala) for treatment of certain severe or rare forms of asthma, according to a press release from the drug’s developer. The biolog.

see more →